Tag Archives: SURPASS

Afami-cel BLA Submission on Track for YE 2023, Lete-cel IND Set to Transition from GSK by YE 2023; MSLN TRuC Programs Deprioritized; Adaptimmune to Advance PRAME Program to the Clinic in 2024; Adaptimmune’s Q3 2023 Earnings Call

On Wednesday, November 8, Adaptimmune held its Q3 2023 earnings call (press release / webcast), confirming that completion of the BLA submission for afami-cel (MAGE-A4 SPEAR-T) is still on track for Q4 2023 while highlighting that the transition of lete-cel (NY-ESO-1 TCR-T) IND from GSK is expected to be closed by YE 2023. Moreover, management anticipated updated milestones for its pipeline assets, including deprioritizing two clinical programs and the selection of a PRAME candidate for clinical development. Below, Celltelligence provides insights on afami-cel potential approval, while discussing Adaptimmune’s pipeline re-prioritization strategy.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

ADP-A2M4CD8 Maintains its Efficacy in MAGE-A4+ Solid Tumors; BNT211 Continues to Impress in Solid Tumors; IM96 Demonstrates Excellent Safety Profile but Modest Preliminary Efficacy in mCRC; ESMO 2023 Analysis 2

ESMO 2023 Analysis 2: Adaptimmune, BioNTech, and Immunochina presented clinical updates from their CAR-T programs in solid tumors. Below, Celltelligence provides insights and context on key selected presentations: 

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Adaptimmune and TCR2 Tx to Discuss Merger at the End of May; Completion of Afami-cel’s rolling BLA Submission Remains on Track; Adaptimmune’s and TCR2 Tx’s Q1 2023 Earnings Call Summary

On Friday, May 12, Adaptimmune held its Q1 2023 earnings call (press release) highlighting that the company will host a General Meeting on May 30 to evaluate the merger with TCR2 Tx while confirming that afami-cel’s (autologous MAGE-A4 SPEAR-T) rolling BLA submission is expected to be completed in mid-2023. Similarly, TCR2 Tx confirmed a special stockholder meeting to endorse the deal with Adaptimmune on the same day (press release). Below, Celltelligence provides insights on the importance of the approval of the merger for both companies, while discussing Adaptimmune’s anticipated plans for its MAGE-A4 assets.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Afami-cel’s Rolling BLA Submission to Initiate in Q4 2022; Adaptimmune Prioritizes MAGE-A4 and PRAME Assets; No Major Updates for Gavo-cel and TC-510; Adaptimmune and TCR2 Tx Q3 2022 Earnings Summaries

On Tuesday, November 8, 2022, Adaptimmune held its Q3 2022 earning call (press release) highlighting that afami-cel’s (MAGE-A4 SPEAR-T) rolling BLA submission for synovial sarcoma will initiate in Q4 2022. Additionally, management announced that they will focus exclusively on MAGE-A4 and PRAME assets, while deprioritizing or pausing the development of non-core programs. On the same day, TCR2 Tx reported its Q3 2022 financials and business updates (press release) highlighting positive topline results from gavo-cel’s (TC-210; autologous mesothelin TRuC-T) Ph1/2 trial in mesothelin-expressing solid tumors. Below, Celltelligence provides insights on Adaptimmune’s pipeline prioritization strategy after GSK’s transfer of assets, while discussing potential delays in TCR2 Tx’s programs.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Clinical Updates from ADP-A2M4CD8’s SURPASS Study; Adaptimmune to Evaluate Multiple Combinations in the SURPASS Program; Adaptimmune’s ESMO 2022 Investor Event

On Friday, September 9, Adaptimmune held their ESMO 2022 Investor Event (press release / presentation) highlighting the clinical results from ADP-A2M4CD8’s (next-gen MAGE-A4 SPEAR-T) Ph1 SURPASS trial presented at ESMO 2022. Moreover, management disclosed future plans for the SURPASS family of trials. Below, Celltelligence provides insights on ADP-A2M4CD8’s updated clinical results, while discussing Adaptimmune’s new strategy to combine ADP-A2M4CD8 with checkpoint inhibitors.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.